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doi:10.1Objective:Gastrointestinal blood flow can be compromised during and after cardiopulmonary bypass. Endothe-
lin has been shown to be involved in the intestinal microcirculatory disturbance of sepsis. The aim of the present
study was to analyze the involvement of the endothelin system on intestinal blood flow regulation during car-
diopulmonary bypass and the effect of vasopressin given during cardiopulmonary bypass.
Methods:A total of 24 pigs were studied in 4 groups (n¼ 6): group I, sham; group II, ischemia/reperfusion with
1 hour of superior mesenteric artery occlusion; group III, cardiopulmonary bypass for 1 hour; and group IV, 1
hour of cardiopulmonary bypass plus vasopressin administration, maintaining the baseline arterial pressure. All
the pigs were reperfused for 90 minutes. During the experiment, the hemodynamics and jejunal microcirculation
were measured continuously. The jejunal mucosal expression of endothelin-1 and its receptor subtypes A and B
were determined using polymerase chain reaction.
Results: During cardiopulmonary bypass, superior mesenteric artery flow was preserved but marked jejunal
microvascular impairment occurred compared with baseline (mucosal capillary density, 192.2  5.4 vs
150.8  5.1 cm/cm2; P ¼ .005; tissue blood flow, 501.7  39.3 vs 332.3  27.9 AU; P ¼ .025). The expression
of endothelin-1 after cardiopulmonary bypass (3.2 0.4 vs 12.2 0.8 RQ, P¼ .006) and endothelin subtype A
(0.7  0.2 vs 2.4  0.6 RQ; P ¼ .01) was significantly increased compared to the sham group. Vasopressin ad-
ministration during cardiopulmonary bypass led to normal capillary density (189.9 3.9 vs 178.0 6.3; P¼ .1)
and tissue blood flow (501.7  39.3 vs 494.7  44.4 AU; P ¼ .4) compared with baseline. The expression of
endothelin-1 (3.2  0.4 vs 1.8  0.3 RQ; P ¼ .3) and endothelin subtype A (0.7  0.2 vs 0.9  0.2 RQ;
P ¼ .5) was not different from the sham group.
Conclusions: Cardiopulmonary bypass leads to microvascular impairment of jejunal microcirculation, which is
associated with the upregulation of endothelin-1 and endothelin subtype A. The administration of vasopressin
minimizes these cardiopulmonary bypass-associated alterations. (J Thorac Cardiovasc Surg 2013;145:539-47)E
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SThe incidence of gastrointestinal complications after car-
diac surgery with cardiopulmonary bypass (CPB) has
been reported to range from 1% to 3%.1,2 Nonocclusive
mesenteric ischemia (NOMI) is the most dreaded of these
complications with mortality rates of up to 90%.1,2
It is considered an extreme reduction or maldistribution
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The Journal of Thoracic and Caof low cardiac output1,2 and sepsis.3 The endothelin (ET)
system has been shown to be involved in sepsis-related
NOMI.4 If NOMI occurs, it commonly affects ileum and
distal jejunum most severely.1
The clinical risk factors for the development of mesenteric
ischemia are hypovolemic shock,1,2 severe heart failure
and cardiogenic shock,1,2 administration of a-adrenergic
drugs,1,2,5 or the use of an intra-aortic balloon pump.1,2 The
evidence regarding vasoconstrictors is mixed. Catechol-
amines acting by way of the a-adrenoceptors have been
proposed to have a negative effect on small bowel
microcirculation after CPB,5,6 a positive effect in sepsis,3,7
and no effect in normal animals.8 The stimulation of b-recep-
tors, however, has been shown to increase intestinal oxygen
consumption.9 Vasopressin, being independent of adrenocep-
tors, has been found to decrease intestinal mucosal perfusion
after CPB10 and in sepsis11,12; it has also been reported to
normalize intestinal blood flow in septic shock.7
The reduction of jejunal tissue blood flow during CPB
has already been documented using laser Doppler or micro-
sphere techniques.5,13 Nonetheless, the question remains
of whether a specific pathophysiologic mechanism pre-
disposes cardiac surgical patients to the occurrence ofrdiovascular Surgery c Volume 145, Number 2 539
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
ET ¼ endothelin
ET-1 ¼ endothelin-1
ETA ¼ ET receptor A
ETB ¼ ET receptor B
NOMI ¼ nonocclusive mesenteric ischemia
SMA ¼ superior mesenteric artery
SVR ¼ systemic vascular resistance
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SNOMI (ie, impairment of splanchnic blood flow beyond the
phase of extracorporeal circulation).
We decided to study the effects of extracorporeal circula-
tion with and without vasopressor support on mesenteric
perfusion in an animal model. To avoid the differential ef-
fects of catecholamines on the a- and b-receptors, we chose
vasopressin for this experiment. Because the ET system has
found to be involved in the regulation of splanchnic blood
flow in septic shock,4 we particularly focused on ET-1
and ET receptor expression.METHODS
A total of 24 domestic pigs with a body weight of 28 to 32 kg were used
for the experiments. The governmental animal care committee approved
the present study.
All pigs in the present study received humane care in compliancewith the
Principles of Laboratory Animals, formulated by the National Society for
Medical Research, and theGuide for the Care and Use of Laboratory Animal
Resource, published by the National Institutes of Health (Bethesda, Md).
Animal Preparation
The pigs were provided a 5-day diet, followed by fasting for 48 hours,
with free access to water to minimize the gastrointestinal tract contents.
They were premedicated with ketamin (15 mg/kg), azaperon (3 mg/kg), at-
ropine sulfate (0.5 mg), and midazolame (15 mg) injected intramuscularly.
Anesthesia was induced with sodium-thiopental (3 mg/kg) and piritramide
(7.5 mg), given intravenously. The pigs were intubated and placed on me-
chanical ventilation, with a fraction of inspired oxygen of 0.3. Anesthesia
was maintained by infusion of sodium-thiopental (0.4–0.5 mg/kg/h) and
piritramide (0.25–0.5 mg/kg/h). Fluid replacement by full electrolyte solu-
tion (Sterofundin; B. Braun, Melsungen, Germany) at a rate of 10 mL/kg/h
was given. Intraoperative blood loss was replaced by gelatine solution
(Gelafundin, B. Braun). The body temperature was maintained at 37.5C
by heating.
Animal Instrumentation
Catheters were introduced in both femoral arteries, and a pulmonary ar-
tery catheter was inserted by way of femoral vein access. After a median
laparotomy, a urinary catheter was inserted, and the superior mesenteric ar-
tery (SMA) was dissected. A transit-time Doppler flow meter (Medistim
ASA, Oslo, Norway) and a tourniquet were passed around the vessel. A
catheter was introduced into the superior mesenteric vein.
A distal jejunal laser Doppler fluxmetry probe was sutured on the se-
rosal surface approximately 3 m distal to the ligament of Treitz using 4 in-
terrupted stitches. The tissue was illuminated with coherent laser light for
determination of the mucosal blood flow (830 nm and 30 mW) and white
light for tissue oxygenation (500–800 nm and 20 W) from a combined540 The Journal of Thoracic and Cardiovascular Surgdiode (fiber separation of 1 mm) through a fiberoptic light guide (O2C,
Lea Medizintechnik, Giessen, Germany). An intravital microscope (Imag-
ing Unit [103] with LED FA series, MicroVision Medical, Amsterdam,
The Netherlands) was placed on the serosal surface 20 to 30 cm from the
laser Doppler probe. Sternotomy was performed, and a left atrial catheter
was inserted.
Study Protocol
The 24 pigs were randomized to 4 groups (n¼ 6): group I, sham; group
II, ischemia/reperfusion (the SMAwas occluded for 1 hour followed by 90
minutes of reperfusion); group III, normothermic nonpulsatile CPB for 1
hour followed by 90 minutes of post-CPB perfusion; and group IV, normo-
thermic nonpulsatile CPB for 1 hour with continuous infusion of vasopres-
sin (0.006 0.0003 U/min/kg) for 50 minutes to maintain the mean arterial
pressure at the baseline level followed by 90 minutes of post-CPB perfu-
sion. The vasopressin infusion was stopped 10 minutes before discontinu-
ation of CPB and aortic decannulation.
CPB Setup
After obtaining baseline measurements in groups III (CPB) and IV
(CPB plus vasopressin), heparin (500 U/kg) was administered, and the
pigs were connected to extracorporeal circulation using ascending aortic
and right atrial cannulation. A membrane oxygenator (Quadrox, Jostra,
Hirrlingen, Germany) was used. The circuit was primed with 500 mL
full electrolyte solution (Sterofundin, B. Braun) and 500 mL gelatine solu-
tion (Gelafundin, B. Braun). Normothermia was maintained throughout the
experiment. The pump flowwas adjusted to the baseline cardiac output. Af-
ter discontinuation of right atrial cannulation, heparin was antagonized
with protamin sulphate (500 U/kg).
Measurements
The mean arterial blood pressure, central venous pressure, and left atrial
pressure were measured continuously. Cardiac output was measured using
a continuous thermodilution method (Swan-Ganz continuous cardiac out-
put, mixed venous oxygen saturation monitoring catheter; Edwards Life-
science, Pullach, Germany). SMA blood flow, tissue oxygenation, and
mucosal blood flow were measured continuously. Arterial and mesenteric
vein blood samples were taken at defined points: baseline, ischemia/CPB
20 minutes, reperfusion 2 minutes, reperfusion 30 minutes, reperfusion
60 minutes, and reperfusion 90 minutes. Vessel density was recorded at
the corresponding points and at ischemia/CPB 50minutes. Systemic vascu-
lar resistance (SVR) was calculated as (mean arterial blood pressurecen-
tral venous pressure)/cardiac output.
Intravital Microscopy
Microscopic images were obtained using a mobile intravital microscope
(MicroVision Medical), recorded on video (50 Hz; Panasonic, Osaka, Ja-
pan), and subsequently analyzed off-line. The capillary diameters were de-
termined using a computer-assisted image analysis system (CapImage;
Zeintl Software, Heidelberg, Germany). The functional capillary density
was measured as the length of the perfused capillaries per observation field
and expressed in centimeters per square centimeters.
Clinical Chemistry Analysis
ET-1 and lactate were determined in plasma from the arterial and mes-
enteric venous blood samples (Assay Designs, Immunoassay Kit, catalog
no. 900-020A; ABL-System 615, Radiometer, Copenhagen, Denmark).
RNA Extraction and cDNA Synthesis
At the end of the experiment, biopsies were obtained from the jeju-
num (close to the measurement of laser Doppler flow) and femoral
muscle.ery c February 2013
Bomberg et al Evolving Technology/Basic ScienceThe specimens were immediately frozen in liquid nitrogen and stored at
80C until analysis. The total cellular RNA of the jejunal mucosa was iso-
lated using the Qiagen RNeasy Mini Reagent Set (RNeasy Mini Kit No.
74104; Qiagen, Hilden, Germany). The muscle total cellular RNAwas iso-
lated using the Qiagen RNeasy Mini Reagent Set (RNeasy Fibrous Tissue
Mini Kit No. 74704; Qiagen) according to the manufacturer’s recommen-
dations. RNA preparation and handling was performed in a laminar flow
hood under RNAse free conditions. The RNA concentration and purity
was determined by spectrophotometry. The RNA concentration was greater
than 100 ng/mL, and the solution was stored at80C until further analysis.
The purified RNA was transcribed into cDNA in a reverse transcriptase-
polymerase chain reaction (PCR). For the cDNA synthesis, the TaqMan
Reverse Transcription Reagents Kit (No. N808-0234; Applied Biosystems,
Darmstadt, Germany) was used.
Real-Time PCR
TaqMan real-time quantitative PCR amplification reactions were per-
formed in a StepOne Plus Real-Time PCR System (Applied Biosystems).
Each preparation consisted of 10 mL TaqMan Gene Expression Master
Mix (TaqMan Gene ExpressionMaster Mix No. 4369016; Applied Biosys-
tems), 1 mL TaqMan Gene Expression Assay (TaqMan Gene Expression
Assay, endothelin-1 [Ss03392453_m1], endothelin receptor A
[Ss03394412_m1], endothelin receptor B [Ss03379833_u1], HPRT1
[Ss03388274_m1]; Applied Biosystems), 2 mL sample (each with 25 ng
cDNA) and 7 mL distilled water. The endogenous control was the
HPRT1 housekeeping gene.
The complete amplification process contained 45 cycles. All TaqMan
PCR data were documented using SDS software (Applied Biosystems).FIGURE 1. A, Cardiac output (L/min) and (B) systemic vascular resistance (S
mesenteric artery (SMA) or cardiopulmonary bypass (CPB). *P<.05 vs sham
The Journal of Thoracic and CaLinear regression and correlation analysis of real-time PCR amplifica-
tion data were performed using SDS software (Applied Biosystems). The
gene expression was analyzed using the relative quantification approach
(Applied Biosystems). A ratio of target tissue and muscle tissue was calcu-
lated (RQ).14 The quantity calculated for the target subunit was normalized
with HPRT1 as the endogenous control. The normalized value of the con-
trol (sham) group was taken as the calibrator to calculate the relative ex-
pression levels of the target genes in the experimental groups.
Statistical Analysis
The data are presented as the mean  standard error of the mean. Sta-
tistical analysis was performed with SigmaStat, version 3.1 (Jandel Sci-
entific, San Rafael, Calif). The statistical significance of the changes
from baseline within each group was tested with analysis of variance
for repeated measurements and the post hoc test. Differences among
the groups were analyzed using 1-way analysis of variance, followed
by a post hoc analysis, including the correction of a-error according to
Bonferroni to compensate for multiple comparisons. If the values did
not show a normal distribution, analysis of variance for nonparametric
values (Kruskal-Wallis test) was used with the multiple comparison
method (Dunn or Bonferroni method). Statistical significance was ac-
cepted at an error probability of P  .05.
RESULTS
Hemodynamic Parameters
In group I, all measured parameters remained constant
throughout the experiment (Figure 1 and Table 1).VR) [(dyn 3 sec) 3 cm5]. Intervention: 1-hour occlusion of the superior
group; yP<.05 vs baseline; #P<.05 vs CPB group. Vaso, Vasopressin.
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TABLE 1. Blood analysis, jejunal capillary density, and oxygen saturation
Variable Baseline
Intervention (min) Reperfusion (min)
20 50 60 2 30 60 90
Capillary density (cm/cm2)
Sham 196.3  4.2 196.9  3.4 197.9  4.3 — 198.2  4.3 196.3  5.2 193.2  2.8 192.0  4.8
Ischemia 193.0  2.7 0.0  0.0*,y,z 0.0  0.0*,y,z — 145.3  2.0*,y 169.5  2.3*,y 134.6  2.9*,y,z 124.1  2.9*,y,z
CPB 192.2  5.4 150.8  5.1*,y 143.3  7.4*,y — 160.3  3.2*,y 156.6  7.4*,y 171.0  8.3*,y 168.5  8.5*,y
CPB, Vaso 189.6  3.9 178.0  6.3z 178  4.4z — 174.2  4.6*,y 156.2  9.6*,y 172.0  6.8*,y 165.8  4.6*,y
Jejunal oxygen saturation (%)
Sham 58.3  4.4 62.4  2.9 61.8  2.1 62.2  2.2 62.0  2.6 62.3  2.6 59.7  2.1 58.7  2.0
Ischemia 61.6  2.2 10.0  1.9*,y,z 8.7  1.1*,y 8.3  1.0*,y,z 57.7  5.2 73.4  1.6*,y,z 71.9  2.0*,y,z 69.4  2.1*,y,z
CPB 64.1  2.7 48.7  3.2*,y 47.5  2.1*,y 47.3  2.0*,y 64.5  3.2 62.7  2.5 59.6  3.4 57.9  3.3
CPB, Vaso 59.7  2.5 60.1  2.5z 61.1  2.4z 57.0  3.1z 68.3  2.3* 68.5  1.1* 66.6  2.0* 63.3  1.6
Arterial Hct (%)
Sham 23.0  1.1 22.1  0.9 — — 22.2  1.6 20.4  1.4 20.0  1.1 19.4  1.2
Ischemia 23.5  1.2 21.5  1.1z — — 22.2  1.4z 20.5  1.5 20.0  1.7 18.2  1.1
CPB 24.5  1.2 17.8  0.9*,y — — 18.5  0.5*,y 17.8  0.7*,y 16.7  1.0*,y 16.3  0.6*,y
CPB, Vaso 22.5  1.0 17.3  0.3*,y — — 18.2  0.9*,y 16.3  1.0*,y 15.7  1.0*,y 15.2  1.0*,y
Lactate concentrationx (mmol/L)
Sham 0.4  0.2 0.2  0.1 — — 0.4  0.2 0.2  0.1 0.3  0.1 0.1  0.1
Ischemia 0.3  0.2 3.5  0.9*,y — — 2.1  0.4*,y 1.1  0.2*,y 0.9  0.2 0.4  0.1
CPB 0.1  0.1 0.3  0.1 — — 0.6  0.1 0.1  0.1 0.3  0.1 0.4  0.1
CPB, Vaso 0.3  0.1 0.3  0.1 — — 0.3  0.1 0.2  0.1 0.6  0.1 0.6  0.1
Arterial ET-1 (pg/mL)
Sham 6.2  0.5 6.5  0.5 — — 6.3  0.6 6.2  0.8 5.8  0.6 6.1  0.7
Ischemia 6.1  0.5 7.4  0.5y — — 7.9  0.5*,y,z 6.4  0.5 6.7  0.5 6.5  0.4
CPB 6.5  0.7 6.5  0.4 — — 6.2  0.6 6.4  0.4 6.4  0.5 6.1  0.4
CPB, Vaso 6.5  0.7 6.5  0.7 — — 6.3  0.6 6.4  0.6 6.4  0.6 6.6  0.6
Intervention: 1-hour occlusion of superior mesenteric artery or cardiopulmonary bypass. CPB, Cardiopulmonary bypass; Vaso, vasopressin; Hct, hematocrit; ET-1, endothelin-1.
*P<.05 vs sham. yP<.05 vs baseline. zP<.05 vs CPB. xDifference between aortic and superior mesenteric vein.
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sion of the intestine was associated with a significant de-
crease in SVR and corresponding alterations in the
cardiac output and mean arterial pressure compared with
baseline (P<.001) and group I (P¼ .025; Table 1). Mesen-
teric blood flow (P ¼ .007) and cardiac output (P ¼ .04)
were significantly increased throughout the reperfusion pe-
riod (Figures 1 and 2).
In group III (CPB), the onset of CPB initiated a significant
decrease in SVR, which remained below baseline and lower
than that in group I (P¼ .005; Figures 1 and 2 and Table 1).
Mesenteric blood flow and cardiac output remained
constant during CPB and increased significantly compared
with baseline during the post-CPB period (P ¼ .007;
Figures 1 and 2).
In group IV (CPB plus vasopressin), SVR remained con-
stant during CPB, with a gradual decrease after termination
of CPB and discontinuation of vasopressin infusion. This
decrease was significant at 30 minutes of reperfusion
(P ¼ .02; Figure 1). A significant decrease in mesenteric
blood flow was observed during CPB compared with that
at baseline (P<.001) and in group III (P ¼ .01) and group
I (P¼ .01). Mesenteric perfusion returned to baseline levels
after termination of CPB (Figure 2).542 The Journal of Thoracic and Cardiovascular SurgMicrocirculation and Oxygen Saturation
In group I, microvascular perfusion and oxygen satura-
tion in the jejunal tissue remained constant (Figure 3 and
Table 1). In group II, a significant decrease was seen in
the microvascular blood flow (P<.001) and oxygen satura-
tion (P<.001; Figure 3 and Table 1) during occlusion of the
SMA. During reperfusion, fast recovery of oxygen satura-
tion occurred within 2 minutes (Table 1) and microvascular
flow slowly returned to baseline within 60 minutes
(Figure 3).
In group III (CPB), the onset of CPB initiated a significant
decrease of jejunal mucosal blood flow (P ¼ .025) and ox-
ygen saturation (P<.001; Figure 2 and Table 1). Mucosal
flow remained less than that at baseline (P ¼ .047) and
that in group I (P ¼ .05) until the end of the experiment
(Figure 3).
In group IV (CPB plus vasopressin), jejunal microvas-
cular flow and oxygen saturation remained constant during
CPB. After discontinuing CPB and vasopressin adminis-
tration, mucosal flow decreased significantly compared
with that at baseline (P ¼ .015) and in group I
(P ¼ .031; Figure 3). Oxygen saturation remained greater
than that at baseline after CPB for 60 minutes (P ¼ .023;
Table 1).ery c February 2013
FIGURE 2. Superior mesenteric artery (SMA) blood flow. Intervention: 1-hour occlusion of the SMA or cardiopulmonary bypass (CPB). *P<.05 vs sham
group; yP<.05 vs baseline; #P<.05 vs CPB group. Vaso, Vasopressin.
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Intravital microscopy in group I revealed constant cap-
illary density in the jejunum (Table 1). In group II, there
was complete cessation of capillary blood flow (ie, loss
of capillary density) during occlusion of the SMA
(P< .001). During reperfusion, the capillary density in-
creased but did not recover to baseline or that of group IThe Journal of Thoracic and Ca(Table 1). In group III (CPB), the onset of CPB initiated
a significant decrease in capillary density (P ¼ .005)
that remained less than that at baseline (P ¼ .027) and
in group I (P < .001) until the end of the experiment
(Figure 4 and Table 1). In group IV (CPB plus vasopres-
sin), the jejunal capillary density remained constant dur-
ing CPB (P ¼ .1). After discontinuing vasopressinrdiovascular Surgery c Volume 145, Number 2 543
FIGURE 3. Distal jejunal mucosal blood flow. Intervention: 1-hour occlusion of the superior mesenteric artery (SMA) or cardiopulmonary bypass (CPB).
*P<.05 vs sham group; yP<.05 vs baseline; #P<.05 vs CPB group. Vaso, Vasopressin.
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creased significantly compared with that baseline and in
group I (P ¼ .02; Figure 4 and Table 1).
Blood Analysis
In groups I and II, the hematocrit remained constant, but
in groups III and IV, there was a significant reduction544 The Journal of Thoracic and Cardiovascular Surgduring CPB (Table 1). The mesenteric venous potassium
level increased significantly during intervention only in
group II. In groups I, III, and IV, the lactate concentration
and arterial ET-1 levels remained constant throughout the
experiment (Table 1). In group II, a significant increase in
the lactate concentration (P ¼ .024) and ET-1 plasma level
(P<.001) was found during occlusion of the SMA. Duringery c February 2013
FIGURE 4. Intravital microscopy images in groups III (cardiopulmonary
bypass [CPB] for 50 minutes) and IV (CPB plus vasopressin for 50 min-
utes) after 50 minutes of intervention.
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utes (Table 1).
Jejunal ET Gene Expression
In group II, the jejunal gene expression of ET-1 was sig-
nificantly elevated compared with that in group I at the end
of the experiment (P ¼ .021; Figure 5).
In group III (CPB), the expression of ET-1 was signifi-
cantly increased compared with that in groups I
(P ¼ .006), II (P ¼ .01), and IV (P ¼ .004; Figure 5).
The expression of ET receptor A (ETA) in this group was
also significantly elevated compared with the expression
in groups I (P ¼ .01), II (P ¼ .03), and IV (P ¼ .01). The
expression of ET receptor B (ETB) was only increased com-
pared with that in group IV (P ¼ .03). In group IV, the ex-
pression of ET-1 and ETA and ETB was comparable to that
in group I and thus significantly lower than that in group III
(P ¼ .004, P ¼ .01, and P ¼ .03, respectively).
DISCUSSION
Extracorporeal circulation leads to a systemic inflamma-
tory response syndrome with hemodynamic changes most
commonly involving vasodilation and the need for
vasopressor treatment.1,2 More recently, a decrease in
circulating vasopressin levels has been described duringFIGURE 5. Jejunal gene expression of endothlin-1 (ET-1) and endothelin
receptor subtypes A and B (ETRA and ETRB). A ratio of target tissue and
muscle tissue was calculated. *P<.05 vs sham group. #P<.05 vs cardio-
pulmonary bypass (CPB). Vaso, Vasopressin.
The Journal of Thoracic and CaCPB.15 Several studies have documented alterations in
intestinal microcirculation during extracorporeal circula-
tion.5,6,13,16 Postoperative nonocclusive mesenteric
ischemia can occur; it is as yet unclear whether NOMI is
simply the delayed result of microcirculatory alterations
initiated during CPB or rather the manifestation of
a separate disease. Alternatively, it can be assumed that
the changes in the microcirculation are a consequence of
the vasopressor treatment necessary in many patients
during and after operations involving CPB.6,15,17
To understand the pathomechanism of NOMI, it, there-
fore, appears necessary to study the physiologic response
of the effect of mesenteric perfusion to CPB. We decided
to study intestinal blood flow on a macroscopic and micro-
scopic level, because the microcirculation might not follow
the regulation of global intestinal blood flow. As controls,
we chose a group of animals without manipulation (apart
from the instrumentation necessary for measurement of
the parameters) and another group with surgical occlusion
of the SMA.
During CPB, we maintained the pump flow at the level
of the baseline cardiac output. As expected, the blood
flow in the SMA was not affected by CPB in our experi-
ments. The jejunal microcirculation, however, showed
a pathologic response in line with that in previous stud-
ies.5,6,13 The decrease in jejunal microcirculation was
not only seen by laser Doppler fluxmetry, but was also
confirmed by intravital microscopy. The changes in
jejunal microcirculation persisted until the end of the
experiment. These observations indicate increased shunt
perfusion at the cost of nutritive flow to the intestinal
wall. Increased arteriovenous shunting has also been
described in a previous study.18
Despite a decrease in total SMA blood flow during CPB
and vasopressin administration, the jejunal microcircula-
tion remained normal. Thus, the reduction in the macro-
scopic blood flow apparently did not have an adverse
effect on tissue perfusion and oxygenation. We assume
that the vasopressin administration in our model decreased
shunt perfusion, possibly by increasing jejunal vascular re-
sistance and leading to preserved jejunal microcirculation.
Only after termination of CPB and vasopressin administra-
tion did we observe a decrease in jejunal capillary density
and microvascular perfusion. This suggests that the lack
of the vasopressin effect on the precapillary muscle tone re-
sulted in increased shunt perfusion.
A significant increase in jejunal ET-1 expression and also
increased arterial ET-1 was found in the ischemia group. In-
creased arterial ET-1 has also been described in a previous
mesenteric ischemia study,4 as well as during CPB.19 A sig-
nificant increase in jejunal ET-1 expression and increased
ETA receptor expression were observed in the CPB group.
These findings are in line with the demonstrated impaired
jejunal microcirculation during CPB. They are alsordiovascular Surgery c Volume 145, Number 2 545
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located on the vascular smooth muscle mediates vasocon-
striction as a response to ET-1.4,19 ETA and ETB are G
protein-coupled receptors, which have been shown to
have a half-life of approximately 40 minutes.20 Thus, our
findings of increased mRNA levels of both ET receptors
appear plausible.
Vasopressin interacts with the ET system and has been re-
ported to evoke ET-1 release from the perfused rat mesen-
teric vascular bed.21 Its clinical use has been reported to
be safe in the context of CPB.15,17 In our experiments, the
vasopressin administration during CPB did not alter the
ET system. In contrast, ET-1, ETA, and ETB remained nor-
mal, and the changes in the ET system were apparently ob-
viated. In addition, vasopressin administration during
extracorporeal circulation resulted in preserved jejunal
microcirculation.
Our results in the vasopressin group—with normal ETA
and ETB expression associated with normal jejunal micro-
circulation—are compatible with previous findings of a pro-
tective effect of ET receptor antagonists in ischemia/
reperfusion injury of the small bowel.4,22 Additionally,
a recent study by Toole and colleagues23 proved the safety
of ETA antagonist treatment in high-risk cardiac surgery pa-
tients. In line with this, the administration of ET-1 has been
shown to result in reduced microvascular flow of the jeju-
num and ileum.24 These findings indicate that the ET sys-
tem plays an active role in intestinal ischemia. The design
of the present experiment did not allow us to determine
the duration of the alterations in the ET system.
Our findings imply an interaction between the ET and
vasopressin systems, although the investigation was not
designed to clarify the possible mechanisms of interac-
tion. The results also indicate that vasopressin could be
a potent and physiologic vasopressor during and after
CPB.17 This is in line with another report that did not
show a negative influence of vasopressin on jejunal
mucosal blood flow.25
Because the study was performed in a porcine model, the
results might not be directly transferable to humans. The
number of pigs in each group was limited; however, efforts
were made to keep temperature, left atrial pressure, and
fluid balance constant. Thus, no significant differences
were found in most of these parameters among the groups.
Additional investigations in patients with nonocclusive
mesenteric ischemia after cardiac surgery are needed to de-
termine the pathophysiologic role of plasma ET-1 levels. If
ET-1 proves to be a major player in the development of
NOMI after cardiac surgery, interventional studies elucidat-
ing the effect of ET-1 receptor antagonists should be
performed. Regarding the potential protective effect of
vasopressin in the treatment of vasodilatory shock after
cardiac surgery, additional studies with hard endpoints are
needed.546 The Journal of Thoracic and Cardiovascular SurgCONCLUSIONS
CPB leads to decreased tissue perfusion of the jejunum.
This seems to be associated with marked upregulation of
ET-1 and ETA. Vasopressin given during CPB appears to
maintain adequate distal jejunal mucosal perfusion during
CPB and to prevent the alterations of the ET system.
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